We are entering another stage of the COVID-19 pandemic.
A panel of advisers to the United States’ Food and Drug Administration (FDA) has voted unanimously to suggest the rollout of Moderna’s COVID-19 booster shots to the initial vaccine for citizens who are 65 years or older, in addition to people with high-risk of serious illness or occupational proximity to the virus, according to an initial report from Reuters.
The vote for Moderna’s booster was 19 to zero; in favor.
While the booster shot still needs formal approval from the FDA to go forward, we could begin seeing increased rollouts soon, despite the fact that “the data itself is not strong,” according to Patrick Moore of the University of Pittsburgh’s school of medicine, in the Reuters report.
Moderna’s COVID-19 vaccine booster was approved
The FDA will still need to approve the booster shot from Moderna, but when this happens, the United States’ Centers for Disease Control and Prevention (CDC) will move forward with concrete recommendations on who should and shouldn’t receive the shots. The FDA’s advisory panel, known as the Vaccines and Related Biological Products Advisory Committee, reached this agreement after a Thursday meeting to reflect on the idea of an additional dose of Moderna’s vaccine. Further consideration is due to take place concerning Johnson & Johnson’s vaccine on Friday.
This is developing news about the FDA advisory panel’s approval of Moderna’s booster shot of its COVID-19 vaccine for older people, so be sure to check in with us for more updates.